Latest research on Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Capecitabine side effects

In the last years, the combination of Capecitabine and temozolomide (Cap/Tem) has gained increased interest given the feasibility of oral administration with limited toxicity and particularly promising ORR. [source, 2016]
In the case of NETs, the initial single Capecitabine administration for 9 days seems to cause the depletion of the MGMT gene, which makes the NETs chemosensitive to temozolomide at day 10. [source, 2016]
Because a 20% dose reduction of Capecitabine still evoked adverse effects (general weakness and electrolyte imbalance), chemotherapy with lapatinib alone was started. [source, 2016]
Stuart Lichtman (Memorial Sloan Kettering Cancer Centre, Commack, USA) drew particular attention to the following possibilities: altered coagulation in patients taking Warfarin and Capecitabine, increased exposure to the active metabolite of Irinotecan when taken together with Ketoconazole, and increased clearance of Imatinib in patients taking St John’s wort, which is an inducer of CYP3A4. [source, 2016]
Interestingly, the addition of Capecitabine increased the response rates to 20 %. [source, 2016]
Although ixabepilone [9] has been shown to increase the overall response rate (ORR) and PFS when combined with Capecitabine, it is also associated with markedly increased toxicities. [source, 2015]
PA-MSHA did not increase the hematologic toxicities of Capecitabine. [source, 2015]
It seems that PA-MSHA did not increase the anticancer effects of Capecitabine in MBC. [source, 2015]
On the other hand, the addition of PA-MSHA to Capecitabine did not increase the toxicity and was well tolerated. [source, 2015]
The addition of PA-MSHA did not increase hematologic or non-hematologic toxicities of Capecitabine in our study. [source, 2015]